Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in Lutherville-Timonium, Maryland, San Diego, California and Austin, Texas.

Trinity Capital Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRESENTED NEW SUBGROUP ANALYSES FROM PHASE 3 CLINICAL TRIAL OF CAN-2409 IN LOCALIZED PROSTATE CANCER AT THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) 2025 MEETING, DEMONSTRATING IMPROVED PROSTATE CANCER-SPECIFIC DISEASE-FREE SURVIVAL (DFS), INDEPENDENT OF RADIATION THERAPY MODALITY UTILIZED COMPANY PLANS TO INITIATE PIVOTAL PHASE 3 CLINICAL TRIAL OF CAN-2409 IN PATIENTS WITH METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC) AND PROGRESSIVE DISEASE, DESPITE IMMUNE CHECKPOINT INHIBITOR (ICI) TREATMENT, IN Q2 2026 ANNOUNCED ENCOURAGING UPDATED SURVIVAL DATA FOR PATIENTS ENROLLED IN ITS PHASE 1B CLINICAL TRIAL OF CAN-3110 (LINOSERPATUREV) IN RECURRENT HIGH-GRADE GLIOMA (RHGG) MANUSCRIPT PUBLISHED IN THE SCIENTIFIC JOURNAL SCIENCE TRANSLATIONAL MEDICINE, REPORTING THE TISSUE RESPONSE TO CAN-3110 BASED ON THE ANALYSIS OF SERIAL TUMOR BIOPSIES FROM TWO PATIENTS TREATED WITH MULTIPLE ADMINISTRATIONS OF CAN-3110 IN ARM C OF THE PHASE 1B CLINICAL TRIAL PLAN TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) FOR CAN-2409 IN INTERMEDIATE-TO-HIGH-RISK LOCALIZED PROSTATE CANCER IN Q4 2026 ENTERED INTO A $130 MILLION TERM LOAN FACILITY WITH TRINITY CAPITAL INC. FOR A $50 MILLION DRAWN DOWN AT CLOSING, WITH ACCESS TO UP TO AN ADDITIONAL $80 MILLION CASH AND CASH EQUIVALENTS OF $87.0M, AS OF SEPTEMBER 30, 2025, PLUS THE UPFRONT PROCEEDS FROM THE TRINITY CAPITAL DEBT FACILITY, STRENGTHENS THE COMPANY'S FINANCIAL POSITION TO FUND INITIATION OF POTENTIALLY REGISTRATIONAL PHASE 3 TRIAL OF CAN-2409 IN NSCLC AND OTHER PLANNED OPERATIONS INTO Q1 2027 NEEDHAM, MASS., NOV. 13, 2025 (GLOBE NEWSWIRE) -- CANDEL THERAPEUTICS, INC. (CANDEL OR THE COMPANY) (NASDAQ: CADL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MULTIMODAL BIOLOGICAL IMMUNOTHERAPIES TO HELP PATIENTS FIGHT CANCER, ANNOUNCED TODAY FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE.

CANDEL THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

RECORD FUNDING OF $471 MILLION TOTAL INVESTMENT INCOME GROWS 22.3% YEAR-OVER-YEAR NET ASSET VALUE REACHES NEW HIGH OF $998 MILLION PHOENIX , NOV. 5, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC. (NASDAQ: TRIN) ("THE COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER30,2025. THIRD QUARTER 2025 HIGHLIGHTS TOTAL INVESTMENT INCOME OF $75.6 MILLION, AN INCREASE OF 22.3% YEAR-OVER-YEAR.

TRINITY CAPITAL INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

PHOENIX , OCT. 23, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC. (NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THE FUNDING OF EQUIPMENT AND OTHER ASSET FINANCING TO BOBBIE, THEMOM-FOUNDED AND LED ORGANIC INFANT FEEDING COMPANY. BOBBIE IS KNOWN FOR ITS AMERICAN-MANUFACTURED, ORGANIC, EUROPEAN-STYLE INFANT FORMULAS DESIGNED WITH SIMPLE, HIGH-QUALITY INGREDIENTS TO SUPPORT HEALTHY DEVELOPMENT.

TRINITY CAPITAL INC. PROVIDES EQUIPMENT FINANCING TO BOBBIE, BOLSTERING DOMESTIC INFANT FORMULA INDUSTRY

PHOENIX , OCT. 21, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC. (NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THE COMMITMENT OF $15 MILLION IN GROWTH CAPITAL TO KARD FINANCIAL, INC., ("KARD"), A COMMERCE MEDIA NETWORKTHAT HELPS FINTECHS AND FINANCIAL INSTITUTIONSDRIVE USAGE, LOYALTY, AND ENGAGEMENT THROUGH MERCHANT-SPECIFICREWARDS. KARD POWERS NEXT-GENERATION REWARDS PROGRAMS THROUGH A FLEXIBLE, API-FIRST PLATFORM THAT ENABLES FINANCIAL INSTITUTIONS, FINTECHS, AND LOYALTY PROGRAMS TO BUILD DEEPLY CUSTOMIZED REWARDS ECOSYSTEMS.

TRINITY CAPITAL INC. PROVIDES $15 MILLION IN GROWTH CAPITAL TO KARD, ACCELERATING GROWTH OF ITS COMMERCE MEDIA NETWORK

PHOENIX , OCT. 14, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC.(NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THE COMMITMENT OF $130 MILLION IN GROWTH CAPITAL TO CANDEL THERAPEUTICS, INC.(NASDAQ: CADL) ("CANDEL"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING VIRAL IMMUNOTHERAPIES TO HELP PATIENTS FIGHT CANCER. CANDEL THERAPEUTICS IS DEVELOPING A CLINICAL PIPELINE OF OFF-THE-SHELF CANCER TREATMENTS THAT AIM TO EMPOWER A PATIENT'S OWN IMMUNE SYSTEM TO FIGHT CANCER.

TRINITY CAPITAL INC. PROVIDES $130 MILLION IN GROWTH CAPITAL TO CANDEL THERAPEUTICS, SUPPORTING DEVELOPMENT OF VIRAL IMMUNOTHERAPIES TO FIGHT CANCER

NEEDHAM, MASS., OCT. 14, 2025 (GLOBE NEWSWIRE) -- CANDEL THERAPEUTICS, INC. (CANDEL OR THE COMPANY) (NASDAQ: CADL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MULTIMODAL BIOLOGICAL IMMUNOTHERAPIES TO HELP PATIENTS FIGHT CANCER, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A FIVE-YEAR, $130 MILLION TERM LOAN FACILITY WITH TRINITY CAPITAL INC. (NASDAQ: TRIN) (TRINITY CAPITAL).

CANDEL THERAPEUTICS ENTERS INTO $130 MILLION TERM LOAN FACILITY WITH TRINITY CAPITAL INC.

COMPANY FUNDS $471 MILLION OF INVESTMENTS IN THE THIRD QUARTER OF 2025 PHOENIX , OCT. 9, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC. (NASDAQ: TRIN) ("TRINITY CAPITAL" OR THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED A PORTFOLIO UPDATE FOR THE THIRD QUARTER AND FIRST THREE QUARTERS OF 2025. TRINITY CAPITAL ORIGINATED $773 MILLION OF NEW COMMITMENTS IN THE THIRD QUARTER OF 2025, BRINGING NEW COMMITMENTS FOR THE FIRST THREE QUARTERS OF 2025 TO $1.5 BILLION.

TRINITY CAPITAL INC. ORIGINATES $773 MILLION OF NEW COMMITMENTS IN THE THIRD QUARTER OF 2025

PHOENIX , OCT. 8, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC.(NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THE APPOINTMENT OF PAUL D'AGROSA AS MANAGING DIRECTOR OF LIFE SCIENCES, BASED IN DENVER, COLORADO. MR. D'AGROSA WILL HELP EXPAND THE COMPANY'S LIFE SCIENCES BUSINESS TO NEW MARKETS ACROSS THE U.S., BRINGING WITH HIM MORE THAN A DECADE OF EXPERIENCE IN LOAN ORIGINATION, BUSINESS DEVELOPMENT, AND RELATIONSHIP MANAGEMENT.

TRINITY CAPITAL INC. EXPANDS LIFE SCIENCES VERTICAL WITH APPOINTMENT OF PAUL D'AGROSA

CHARLOTTE, N.C.--(BUSINESS WIRE)--TOWN LANE AND TRINITY CAPITAL ADVISORS ANNOUNCE UPTOWN CHARLOTTE OFFICE ACQUISITION.

TOWN LANE AND TRINITY CAPITAL ADVISORS' ANNOUNCE ACQUISITION OF 440 SOUTH CHURCH IN UPTOWN CHARLOTTE

PHOENIX , OCT. 7, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC. (NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THAT IT WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS AT8:00 A.M. ETONWEDNESDAY, NOVEMBER 5, 2025.

TRINITY CAPITAL INC. TO ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST EARNINGS CALL ON NOVEMBER 5

PHOENIX , SEPT. 22, 2025 /PRNEWSWIRE/ --TRINITY CAPITAL INC.(NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THE COMMITMENT OF $45 MILLION IN GROWTH CAPITAL TO RAPID MICRO BIOSYSTEMS (NASDAQ: RPID) ("RAPID MICRO"), AN INNOVATIVE LIFE SCIENCES TECHNOLOGY COMPANY PROVIDING MISSION-CRITICAL AUTOMATION SOLUTIONS TO FACILITATE THE EFFICIENT MANUFACTURING AND FAST, SAFE RELEASE OF HEALTHCARE PRODUCTS.

TRINITY CAPITAL INC. PROVIDES $45 MILLION IN GROWTH CAPITAL TO RAPID MICRO BIOSYSTEMS, MODERNIZING HEALTHCARE INDUSTRY PRACTICES

NON-COASTAL VENTURE CAPITAL FIRM AZ-VC ADDS SECOND VINTAGE VEHICLE TO ITS SUCCESSFUL $115 FIRST FUND PHOENIX , SEPT. 19, 2025 /PRNEWSWIRE/ -- AZ-VC , A U.S. VENTURE CAPITAL FIRM FUELING INNOVATION OUTSIDE TRADITIONAL COASTAL MARKETS, TODAY ANNOUNCED THE LAUNCH OF ITS SECOND FUND, AZ-VC II, MANAGING AN UNDISCLOSED AMOUNT IN AN EFFORT TO FOSTER INNOVATION AND MOMENTUM OUTSIDE OF TRADITIONAL U.S. TECH HUBS.

AZ-VC II LAUNCHES TO FILL THE FUNDING GAP FOR NON-COASTAL STARTUPS; ESCHEWS SKY-HIGH COASTAL VALUATIONS

PHOENIX , SEPT. 18, 2025 /PRNEWSWIRE/ -- TRINITY CAPITAL INC. (NASDAQ: TRIN) (THE "COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THE COMMITMENT OF $100 MILLION IN GROWTH CAPITAL TO ANGEL STUDIOS, INC. (NYSE: ANGX) ("ANGEL STUDIOS" OR "ANGEL"), AN UNPRECEDENTED MEDIA AND TECHNOLOGY COMPANY CHAMPIONING VALUES-BASED STORIES.

TRINITY CAPITAL INC. PROVIDES $100 MILLION IN GROWTH CAPITAL TO ANGEL, EXPANDING ITS GLOBAL IMPACT IN VALUES-DRIVEN ENTERTAINMENT

23RD CONSECUTIVE QUARTER OF A CONSISTENT DIVIDEND PHOENIX , SEPT. 17, 2025 /PRNEWSWIRE/ --TRINITY CAPITAL INC.(NASDAQ: TRIN) ("TRINITY CAPITAL" OR "THE COMPANY"), A LEADING ALTERNATIVE ASSET MANAGER, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS DECLARED A CASH DIVIDEND OF $0.51 PER SHARE WITH RESPECT TO THE QUARTER ENDING SEPTEMBER 30, 2025.

Trinity Capital Inc.

TRIN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Trinity Capital Inc.

TRIN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TRIN